Gilead Sciences (GILD) Stock Insights
GILD$159.20+0.12 +0.08%
$197.40B
Market Cap
-61.03
P/E
15.90
Forward P/E
36
Score
Gilead Sciences (GILD) Stock Insights
GILD price $159.20 +0.12 +0.08%
- Ticker
- GILD
- Price
- $159.20
- Change
- +0.12 +0.08%
- Market cap ?
- $197.40B
- P/E ?
- -61.03
- Forward P/E ?
- 15.90
- Dividend yield ?
- 2.05%
- Beta ?
- 0.33
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stocklytics score
- 36
- Value
- 28
- Quality
- 44
- Growth
- 35
Stocklytics score rationale: value 28, quality 44, growth 35.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 30390000000 | 26107000000 | 22127000000 | 22449000000 | 24689000000 | 27305000000 | 27281000000 | 27116000000 | 28754000000 | 29442000000 |
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key…
Fair value
GILD fair value $240.68. Price $159.20. Price is 34% below fair value.
Below fair value, and cheaper than usual. A larger discount than on 90% of days in the past 5 years.
Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.
Calculated with a 10-year free-cash-flow discount. Starting free cash flow 13.20B. Growth 8.65%. When analyst earnings forecasts are available, free cash flow in those years is forecast earnings times the company's usual conversion of earnings into free cash flow, kept between 60% and 130%. Years with fewer than 3 analyst estimates are left out. Growth then fades in a straight line to terminal growth by year 10, starting from the last well-covered year's growth, or from the pace across those years when the final year slows sharply, kept between 0% and 20%. Without those forecasts, year-1 growth is analyst revenue growth for the next full fiscal year, or 5-year historical revenue growth when that forecast is missing, held for five years, then fading in a straight line to terminal growth by year 10. Terminal growth 3.00%. Discount rate 8.70% (beta 0.8). Beta is kept between 0.8 and 2.0, which on its own would make the discount rate 8.7% to 15.3%. The rate is then capped at 12%. A cap is used because a discount above 12% pushes higher-beta stocks further from the price. The discount rate stays at least 5 percentage points above terminal growth. Shares 1.24B. Net debt 17.37B. The earnings value is next-12-months earnings per share, or trailing earnings when that forecast is missing, times the median P/E of the company's industry. That median uses listed stocks worth at least $10 billion with a positive P/E of 100 or below, and the industry needs at least eight of them. Otherwise the sector median is used when that group also has at least eight, then the market median of those large companies. The multiple used is the lower of that median and 1.25 times the stock's own 10-year median P/E, then kept between 8 and 30. If the stock has no 10-year median, the peer median is kept between 8 and 30. Fair value is the average of the cash-flow value and the earnings value when both exist. Card and credit companies use the earnings value only, because changes in customer receivables distort free cash flow. Model uncertainty is high when fair value is more than 60% from the price, or when most of the cash-flow value sits after year 10.
Earnings
| Date | EPS actual | EPS estimate | Revenue | Revenue estimate |
|---|---|---|---|---|
| 2026-10-29 | — | 2.19 | — | 7.80B |
| 2026-08-04 | -6.75 | -7.25 | 7.80B | 7.40B |
| 2026-05-07 | 2.03 | 1.91 | 6.96B | 6.91B |
| 2026-02-10 | 1.86 | 1.81 | 7.92B | 7.69B |
| 2025-10-30 | 2.47 | 2.13 | 7.77B | 7.45B |
| 2025-08-07 | 2.01 | 1.96 | 7.08B | 6.98B |
| 2025-04-24 | 1.81 | 1.78 | 6.67B | 6.81B |
| 2025-02-11 | 1.90 | 1.74 | 7.57B | 7.15B |
| 2024-11-06 | 2.02 | 1.53 | 7.54B | 7.02B |
| 2024-08-08 | 2.01 | 1.61 | 6.95B | 6.70B |
| 2024-04-25 | -1.32 | -1.49 | 6.69B | 6.36B |
| 2024-02-06 | 1.72 | 1.76 | 7.12B | 7.10B |
| 2023-11-07 | 2.29 | 1.91 | 7.05B | 6.42B |
| 2023-08-03 | 1.34 | 1.60 | 6.60B | 6.46B |
| 2023-04-27 | 1.37 | 1.63 | 6.35B | 6.46B |
| 2023-02-02 | 1.67 | 1.50 | 7.39B | 6.64B |
| 2022-10-27 | 1.90 | 1.44 | 7.04B | 6.13B |
| 2022-08-02 | 1.58 | 1.51 | 6.26B | 5.86B |
| 2022-04-28 | 2.12 | 1.77 | 6.59B | 6.29B |
| 2022-02-01 | 0.69 | 1.53 | 7.24B | 6.61B |
| 2021-10-28 | 2.65 | 1.75 | 7.42B | 6.15B |
| 2021-07-29 | 1.87 | 1.76 | 6.22B | 6.22B |
| 2021-04-29 | 2.08 | 2.06 | 6.42B | 6.68B |
| 2021-02-04 | 2.19 | 2.15 | 7.42B | 6.73B |
| 2020-10-28 | 2.11 | 1.83 | 6.58B | 5.92B |
| 2020-07-30 | 1.11 | 1.46 | 5.14B | 6.72B |
| 2020-04-30 | 1.68 | 1.58 | 5.55B | 5.22B |
| 2020-02-04 | 1.30 | 1.68 | 5.88B | 7.55B |
| 2019-10-24 | 1.75 | 1.76 | 5.60B | 5.57B |
| 2019-07-30 | 1.82 | 1.72 | 5.68B | 5.37B |
| 2019-05-02 | 1.76 | 1.61 | 5.28B | 4.83B |
| 2019-02-04 | 1.44 | 1.70 | 5.79B | 6.84B |
| 2018-10-25 | 1.84 | 1.63 | 5.60B | 4.96B |
| 2018-07-25 | 1.91 | 1.55 | 5.65B | 4.61B |
| 2018-05-01 | 1.48 | 1.67 | 5.09B | 5.74B |
| 2018-02-06 | 1.78 | 1.70 | 5.95B | 5.58B |
| 2017-10-26 | 2.27 | 2.13 | 6.51B | 6.11B |
| 2017-07-26 | 2.56 | 2.15 | 7.14B | 6.00B |
| 2017-05-02 | 2.23 | 2.28 | 6.50B | 6.65B |
| 2017-02-07 | 2.70 | 2.61 | 7.32B | 7.08B |
Dividends
Yield 2.04%. Payout ratio 47.04%. Frequency Quarterly.
Safety score 95/100 · Safe. Payout ratio is 47% of earnings. Dividends use less than 40% of free cash flow. Dividends were paid in 12 separate years. Yield is 2.0%, in a range that is usually sustainable.
| Ex-date | Dividend | Record | Payment | Frequency |
|---|---|---|---|---|
| 2026-09-15 | $0.82 | 2026-09-15 | 2026-09-29 | Quarterly |
| 2026-06-15 | $0.82 | 2026-06-15 | 2026-06-29 | Quarterly |
| 2026-03-13 | $0.82 | 2026-03-13 | 2026-03-30 | Quarterly |
| 2025-12-15 | $0.79 | 2025-12-15 | 2025-12-30 | Quarterly |
| 2025-09-15 | $0.79 | 2025-09-15 | 2025-09-29 | Quarterly |
| 2025-06-13 | $0.79 | 2025-06-13 | 2025-06-27 | Quarterly |
| 2025-03-14 | $0.79 | 2025-03-14 | 2025-03-28 | Quarterly |
| 2024-12-13 | $0.77 | 2024-12-13 | 2024-12-30 | Quarterly |
| 2024-09-13 | $0.77 | 2024-09-13 | 2024-09-27 | Quarterly |
| 2024-06-14 | $0.77 | 2024-06-14 | 2024-06-27 | Quarterly |
| 2024-03-14 | $0.77 | 2024-03-15 | 2024-03-28 | Quarterly |
| 2023-12-14 | $0.75 | 2023-12-15 | 2023-12-28 | Quarterly |
| 2023-09-14 | $0.75 | 2023-09-15 | 2023-09-28 | Quarterly |
| 2023-06-14 | $0.75 | 2023-06-15 | 2023-06-29 | Quarterly |
| 2023-03-14 | $0.75 | 2023-03-15 | 2023-03-30 | Quarterly |
| 2022-12-14 | $0.73 | 2022-12-15 | 2022-12-29 | Quarterly |
| 2022-09-14 | $0.73 | 2022-09-15 | 2022-09-29 | Quarterly |
| 2022-06-14 | $0.73 | 2022-06-15 | 2022-06-29 | Quarterly |
| 2022-03-14 | $0.73 | 2022-03-15 | 2022-03-30 | Quarterly |
| 2021-12-14 | $0.71 | 2021-12-15 | 2021-12-30 | Quarterly |
| 2021-09-14 | $0.71 | 2021-09-15 | 2021-09-29 | Quarterly |
| 2021-06-14 | $0.71 | 2021-06-15 | 2021-06-29 | Quarterly |
| 2021-03-12 | $0.71 | 2021-03-15 | 2021-03-30 | Quarterly |
| 2020-12-14 | $0.68 | 2020-12-15 | 2020-12-30 | Quarterly |
| 2020-09-14 | $0.68 | 2020-09-15 | 2020-09-29 | Quarterly |
| 2020-06-11 | $0.68 | 2020-06-12 | 2020-06-29 | Quarterly |
| 2020-03-12 | $0.68 | 2020-03-13 | 2020-03-30 | Quarterly |
| 2019-12-12 | $0.63 | 2019-12-13 | 2019-12-30 | Quarterly |
| 2019-09-12 | $0.63 | 2019-09-13 | 2019-09-27 | Quarterly |
| 2019-06-13 | $0.63 | 2019-06-14 | 2019-06-27 | Quarterly |
| 2019-03-14 | $0.63 | 2019-03-15 | 2019-03-28 | Quarterly |
| 2018-12-13 | $0.57 | 2018-12-14 | 2018-12-28 | Quarterly |
| 2018-09-13 | $0.57 | 2018-09-14 | 2018-09-27 | Quarterly |
| 2018-06-14 | $0.57 | 2018-06-15 | 2018-06-28 | Quarterly |
| 2018-03-15 | $0.57 | 2018-03-16 | 2018-03-29 | Quarterly |
| 2017-12-14 | $0.52 | 2017-12-15 | 2017-12-28 | Quarterly |
| 2017-09-14 | $0.52 | 2017-09-15 | 2017-09-28 | Quarterly |
| 2017-06-14 | $0.52 | 2017-06-16 | 2017-06-29 | Quarterly |
| 2017-03-14 | $0.52 | 2017-03-16 | 2017-03-30 | Quarterly |
| 2016-12-13 | $0.47 | 2016-12-15 | 2016-12-29 | Quarterly |
| 2016-09-14 | $0.47 | 2016-09-16 | 2016-09-29 | Quarterly |
| 2016-06-14 | $0.47 | 2016-06-16 | 2016-06-29 | Quarterly |
| 2016-03-14 | $0.43 | 2016-03-16 | 2016-03-30 | Quarterly |
| 2015-12-14 | $0.43 | 2015-12-16 | 2015-12-30 | Quarterly |
| 2015-09-14 | $0.43 | 2015-09-16 | 2015-09-29 | Quarterly |
| 2015-06-12 | $0.43 | 2015-06-16 | 2015-06-29 | Quarterly |
Insider trades
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-10-15 | Dickinson Andrew D | Sell | 3.00K | $156.22 | 468.66K |
| 2026-10-15 | Mercier Johanna | Sell | 3.00K | $156.22 | 468.66K |
| 2026-10-01 | O'Day Daniel Patrick | Sell | 12.00K | $147.72 | 1.77M |
| 2026-10-01 | O'Day Daniel Patrick | Sell | 3.00K | $148.63 | 445.88K |
| 2026-09-22 | Burkhart Erin | Sell | 2.22K | — | — |
| 2026-09-22 | Burkhart Erin | Buy | 2.22K | — | — |
| 2026-09-22 | Burkhart Erin | Sell | 768 | $152.67 | 117.25K |
| 2026-09-15 | Dickinson Andrew D | Sell | 3.00K | $145.29 | 435.87K |
| 2026-09-15 | Mercier Johanna | Sell | 1.60K | $143.69 | 229.91K |
| 2026-09-15 | Mercier Johanna | Sell | 800 | $144.46 | 115.57K |
| 2026-09-15 | Mercier Johanna | Sell | 600 | $145.29 | 87.17K |
| 2026-09-10 | Dickinson Andrew D | Buy | 2.80K | — | — |
| 2026-09-10 | Dickinson Andrew D | Sell | 1.35K | $144.81 | 195.06K |
| 2026-09-10 | Dickinson Andrew D | Sell | 2.80K | — | — |
| 2026-09-10 | Berger Dietmar | Sell | 533 | — | — |
| 2026-09-10 | Berger Dietmar | Buy | 533 | — | — |
| 2026-09-10 | Berger Dietmar | Sell | 263 | $144.81 | 38.09K |
| 2026-09-10 | Mercier Johanna | Buy | 2.80K | — | — |
| 2026-09-10 | Mercier Johanna | Sell | 1.35K | $144.81 | 195.06K |
| 2026-09-10 | Mercier Johanna | Sell | 2.80K | — | — |
| 2026-09-10 | Cain Wettan Keeley M | Sell | 590 | — | — |
| 2026-09-10 | Cain Wettan Keeley M | Buy | 590 | — | — |
| 2026-09-10 | Cain Wettan Keeley M | Sell | 285 | $144.81 | 41.27K |
| 2026-09-10 | O'Day Daniel Patrick | Buy | 8.78K | — | — |
| 2026-09-10 | O'Day Daniel Patrick | Sell | 4.23K | $144.81 | 612.55K |
| 2026-09-10 | O'Day Daniel Patrick | Sell | 8.78K | — | — |
| 2026-09-01 | O'Day Daniel Patrick | Sell | 1.60K | $147.51 | 236.01K |
| 2026-09-01 | O'Day Daniel Patrick | Sell | 7.99K | $148.36 | 1.19M |
| 2026-09-01 | O'Day Daniel Patrick | Sell | 5.41K | $149.38 | 807.86K |
| 2026-08-26 | WELTERS ANTHONY | Buy | 10.28K | $61.35 | 630.80K |
| 2026-08-26 | WELTERS ANTHONY | Buy | 7.72K | $60.67 | 468.25K |
| 2026-08-26 | WELTERS ANTHONY | Sell | 3.40K | $148.24 | 504.30K |
| 2026-08-26 | WELTERS ANTHONY | Sell | 3.12K | $148.31 | 462.43K |
| 2026-08-26 | WELTERS ANTHONY | Sell | 4.60K | $148.82 | 684.59K |
| 2026-08-26 | WELTERS ANTHONY | Sell | 6.88K | $148.82 | 1.02M |
| 2026-08-26 | WELTERS ANTHONY | Sell | 10.28K | $61.35 | 630.80K |
| 2026-08-26 | WELTERS ANTHONY | Sell | 7.72K | $60.67 | 468.25K |
| 2026-08-20 | Bluestone Jeffrey | Buy | 1.82K | $67.45 | 122.49K |
| 2026-08-20 | Bluestone Jeffrey | Buy | 1.66K | $67.45 | 111.83K |
| 2026-08-20 | Bluestone Jeffrey | Sell | 335 | $61.35 | 20.55K |
| 2026-08-20 | Bluestone Jeffrey | Buy | 1.17K | $67.45 | 78.58K |
| 2026-08-20 | Bluestone Jeffrey | Buy | 335 | $61.35 | 20.55K |
| 2026-08-20 | Bluestone Jeffrey | Buy | 26 | $67.45 | 1.75K |
| 2026-08-20 | Bluestone Jeffrey | Sell | 1.17K | $143.75 | 167.47K |
| 2026-08-20 | Bluestone Jeffrey | Sell | 26 | $146.36 | 3.81K |
| 2026-08-20 | Bluestone Jeffrey | Sell | 1.82K | $144.92 | 263.18K |
| 2026-08-20 | Bluestone Jeffrey | Sell | 335 | $146.26 | 49.00K |
| 2026-08-20 | Bluestone Jeffrey | Sell | 1.66K | $145.73 | 241.62K |
| 2026-08-20 | Bluestone Jeffrey | Sell | 4.67K | $67.45 | 314.65K |
| 2026-08-17 | Dickinson Andrew D | Sell | 3.00K | $138.36 | 415.08K |
| 2026-08-17 | Mercier Johanna | Buy | 1.89K | $72.34 | 136.72K |
| 2026-08-17 | Mercier Johanna | Buy | 23.11K | $66.64 | 1.54M |
| 2026-08-17 | Mercier Johanna | Sell | 16.53K | $137.37 | 2.27M |
| 2026-08-17 | Mercier Johanna | Sell | 11.47K | $138.04 | 1.58M |
| 2026-08-17 | Mercier Johanna | Sell | 1.89K | $72.34 | 136.72K |
| 2026-08-17 | Mercier Johanna | Sell | 23.11K | $66.64 | 1.54M |
| 2026-08-10 | Cain Wettan Keeley M | Sell | 6.00K | — | — |
| 2026-08-10 | Cain Wettan Keeley M | Buy | 6.00K | — | — |
| 2026-08-10 | Cain Wettan Keeley M | Sell | 2.91K | $133.06 | 386.94K |
| 2026-08-03 | O'Day Daniel Patrick | Sell | 6.70K | $129.66 | 868.71K |
| 2026-08-03 | O'Day Daniel Patrick | Sell | 7.70K | $130.80 | 1.01M |
| 2026-08-03 | O'Day Daniel Patrick | Sell | 600 | $131.34 | 78.81K |
| 2026-07-15 | Dickinson Andrew D | Sell | 3.00K | $129.93 | 389.78K |
| 2026-07-15 | Mercier Johanna | Sell | 3.00K | $129.92 | 389.76K |
| 2026-07-01 | O'Day Daniel Patrick | Sell | 11.90K | $126.09 | 1.50M |
| 2026-07-01 | O'Day Daniel Patrick | Sell | 3.10K | $127.08 | 393.93K |
| 2026-06-15 | Mercier Johanna | Sell | 1.48K | $123.42 | 182.66K |
| 2026-06-15 | Mercier Johanna | Sell | 1.07K | $124.00 | 132.68K |
| 2026-06-15 | Mercier Johanna | Sell | 450 | $125.40 | 56.43K |
| 2026-06-15 | Dickinson Andrew D | Sell | 3.00K | $125.40 | 376.20K |
| 2026-06-10 | Berger Dietmar | Sell | 533 | — | — |
| 2026-06-10 | Berger Dietmar | Buy | 533 | — | — |
| 2026-06-10 | Berger Dietmar | Sell | 263 | $121.48 | 31.95K |
| 2026-06-10 | Cain Wettan Keeley M | Sell | 589 | — | — |
| 2026-06-10 | Cain Wettan Keeley M | Buy | 589 | — | — |
| 2026-06-10 | Cain Wettan Keeley M | Sell | 283 | $121.48 | 34.38K |
| 2026-06-10 | Dickinson Andrew D | Buy | 2.80K | — | — |
| 2026-06-10 | Dickinson Andrew D | Sell | 1.34K | $121.48 | 162.90K |
| 2026-06-10 | Dickinson Andrew D | Sell | 2.80K | — | — |
| 2026-06-10 | Mercier Johanna | Buy | 2.80K | — | — |
| 2026-06-10 | Mercier Johanna | Sell | 1.34K | $121.48 | 162.90K |
| 2026-06-10 | Mercier Johanna | Sell | 2.80K | — | — |
| 2026-06-10 | O'Day Daniel Patrick | Buy | 8.78K | — | — |
| 2026-06-10 | O'Day Daniel Patrick | Sell | 4.21K | $121.48 | 511.80K |
| 2026-06-10 | O'Day Daniel Patrick | Sell | 8.78K | — | — |
| 2026-06-01 | O'Day Daniel Patrick | Sell | 10.90K | $131.10 | 1.43M |
| 2026-06-01 | O'Day Daniel Patrick | Sell | 3.06K | $132.22 | 404.84K |
| 2026-06-01 | O'Day Daniel Patrick | Sell | 1.04K | $132.97 | 138.02K |
| 2026-05-15 | Dickinson Andrew D | Sell | 3.00K | $132.27 | 396.81K |
| 2026-05-15 | Mercier Johanna | Buy | 25.00K | $66.64 | 1.67M |
| 2026-05-15 | Mercier Johanna | Sell | 7.75K | $130.29 | 1.01M |
| 2026-05-15 | Mercier Johanna | Sell | 11.18K | $131.19 | 1.47M |
| 2026-05-15 | Mercier Johanna | Sell | 8.37K | $132.23 | 1.11M |
| 2026-05-15 | Mercier Johanna | Sell | 700 | $132.75 | 92.93K |
| 2026-05-15 | Mercier Johanna | Sell | 25.00K | $66.64 | 1.67M |
| 2026-04-30 | Bluestone Jeffrey | Buy | 1.15K | — | — |
| 2026-04-30 | Bluestone Jeffrey | Buy | 4.88K | $130.84 | 639.02K |
| 2026-04-30 | BARTON JACQUELINE K | Buy | 1.15K | — | — |
| 2026-04-30 | BARTON JACQUELINE K | Buy | 4.88K | $130.84 | 639.02K |
| 2026-04-30 | Horning Sandra | Buy | 1.15K | — | — |
Institutional holders
Latest filed quarter: Q2 2026.
Institutions holding: 2.38K, holders -37 vs prior quarter. Ownership 90.19%.
| Holder | Shares | Change | Change % | Value |
|---|---|---|---|---|
| BLACKROCK, INC. | 121.84M | 2.83M | +2.38% | 15.39B |
| VANGUARD CAPITAL MANAGEMENT LLC | 81.09M | 436.96K | +0.54% | 10.25B |
| FMR LLC | 66.87M | -5.04M | -7.00% | 8.45B |
| STATE STREET CORP | 61.22M | 1.36M | +2.27% | 7.73B |
| CAPITAL WORLD INVESTORS | 40.99M | -294.96K | -0.71% | 5.18B |
| INVESCO LTD. | 39.82M | 13.76M | +52.83% | 5.03B |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 35.32M | 186.70K | +0.53% | 4.46B |
| GEODE CAPITAL MANAGEMENT, LLC | 30.07M | 339.59K | +1.14% | 3.80B |
| PRICE T ROWE ASSOCIATES INC /MD/ | 30.00M | 3.75M | +14.28% | 3.79B |
| MORGAN STANLEY | 24.00M | 705.06K | +3.03% | 3.03B |
| DODGE & COX | 23.68M | -573.26K | -2.36% | 2.99B |
| NORGES BANK | 21.97M | 21.97M | New | 2.78B |
| JPMORGAN CHASE & CO | 20.82M | -13.17M | -38.75% | 2.63B |
| CAPITAL RESEARCH GLOBAL INVESTORS | 19.39M | -7.73M | -28.51% | 2.45B |
| BANK OF AMERICA CORP /DE/ | 18.65M | -1.33M | -6.66% | 2.36B |
| BANK OF NEW YORK MELLON CORP | 15.26M | 210.78K | +1.40% | 1.93B |
| NORTHERN TRUST CORP | 13.83M | 7.63K | +0.06% | 1.75B |
| UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC | 12.99M | -212.51K | -1.61% | 1.64B |
| WELLINGTON MANAGEMENT GROUP LLP | 12.70M | -838.31K | -6.19% | 1.60B |
| GOLDMAN SACHS GROUP INC | 10.78M | -286.92K | -2.59% | 1.36B |
| LEGAL & GENERAL GROUP PLC | 10.42M | -43.76K | -0.42% | 1.32B |
| AMUNDI | 9.77M | -766.67K | -7.27% | 1.23B |
| NUVEEN, LLC | 8.34M | 503.37K | +6.43% | 1.05B |
| SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. | 8.16M | 8.16M | New | 1.03B |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 8.16M | -26.50K | -0.32% | 1.03B |
Insights
- Revenue by product
- Revenue by region
| Period | Value |
|---|---|
| FY2011 | Volibris Product: 9800000.0 |
| FY2012 | Ambisome: 346646000.0, Antiviral Products: 8141790000.0, Atripla: 3574483000.0, Complera Eviplera: 342200000.0, Emtriva: 29449000.0, Hepsera: 108315000.0, Letairis: 410054000.0, Other Products: 126932000.0, Ranexa: 372949000.0, Stribild: 57536000.0, Truvada: 3181110000.0, Viread: 848697000.0 |
| FY2013 | Ambisome: 351827000.0, Antiviral Products: 9339879000.0, Atripla: 3648496000.0, Complera Eviplera: 809452000.0, Emtriva: 27405000.0, Hepsera: 81095000.0, Letairis: 519966000.0, Other Products: 143399000.0, Ranexa: 448624000.0, Sovaldi: 139435000.0, Stribild: 539256000.0, Truvada: 3135771000.0, Viread: 958969000.0 |
| FY2014 | Ambisome: 388000000.0, Antiviral Products: 22791000000.0, Atripla: 3470000000.0, Complera Eviplera: 1228000000.0, Harvoni: 2127000000.0, Letairis: 595000000.0, Other antiviral products: 88000000.0, Other Products: 167000000.0, Ranexa: 510000000.0, Sovaldi: 10283000000.0, Stribild: 1197000000.0, Truvada: 3340000000.0, Viread: 1058000000.0, Zydelig: 23000000.0 |
| FY2015 | Ambisome: 350000000.0, Antiviral Products: 30207000000.0, Atripla: 3134000000.0, Complera Eviplera: 1427000000.0, Genvoya: 45000000.0, Harvoni: 13864000000.0, Letairis: 700000000.0, Other antiviral products: 69000000.0, Other Products: 174000000.0, Ranexa: 588000000.0, Sovaldi: 5276000000.0, Stribild: 1825000000.0, Truvada: 3459000000.0, Viread: 1108000000.0, Zydelig: 132000000.0 |
| FY2016 | Ambisome: 356000000.0, Antiviral Products: 27745000000.0, Atripla: 2605000000.0, Complera Eviplera: 1457000000.0, Descovy: 298000000.0, Epclusa: 1752000000.0, Genvoya: 1484000000.0, Harvoni: 9081000000.0, Letairis: 819000000.0, Odefsey: 329000000.0, Other antiviral products: 72000000.0, Other Products: 188000000.0, Ranexa: 677000000.0, Sovaldi: 4001000000.0, Stribild: 1914000000.0, Truvada: 3566000000.0, Viread: 1186000000.0, Zydelig: 168000000.0 |
| FY2017 | Ambisome: 366000000.0, Antiviral Products: 23336000000.0, Atripla: 1806000000.0, Complera Eviplera: 966000000.0, Descovy: 1218000000.0, Epclusa: 3510000000.0, Genvoya: 3674000000.0, Harvoni: 4370000000.0, Letairis: 887000000.0, Odefsey: 1106000000.0, Other antiviral products: 196000000.0, Other Products: 207000000.0, Ranexa: 717000000.0, Sovaldi: 964000000.0, Stribild: 1053000000.0, Truvada: 3134000000.0, Viread: 1046000000.0, Vosevi: 293000000.0, Zydelig: 149000000.0 |
| FY2018 | Products, Other HIV: 61000000.0 |
| FY2019 | Products, Other HIV: 47000000.0 |
| FY2020 | Cell Therapy Products, Total Cell Therapy Product Sales: 607000000.0, Other Products, Total Other product sales: 1886000000.0, Products, Other HIV: 16996000000.0 |
| FY2021 | Cell Therapy Products, Total Cell Therapy Product Sales: 1047000000.0, Hepatitis B Virus / Hepatitis Delta Virus Product: 969000000.0, Other Products, Total Other product sales: 1027000000.0, Products, Other HIV: 16365000000.0, Trodelvy: 380000000.0, Veklury: 5565000000.0 |
| FY2022 | Cell Therapy Products, Total Cell Therapy Product Sales: 1758000000.0, Hepatitis B Virus / Hepatitis Delta Virus Product: 988000000.0, Other Products, Total Other product sales: 946000000.0, Products, Other HIV: 17251000000.0, Trodelvy: 680000000.0, Veklury: 3905000000.0 |
| FY2023 | Cell Therapy Products, Total Cell Therapy Product Sales: 2239000000.0, Hepatitis B Virus / Hepatitis Delta Virus Product: 1017000000.0, Other Products, Total Other product sales: 859000000.0, Products, Other HIV: 18231000000.0, Trodelvy: 1063000000.0, Veklury: 2184000000.0 |
| FY2024 | Cell Therapy Products, Total Cell Therapy Product Sales: 2376000000.0, Other Products, Total Other product sales: 889000000.0, Products, Other HIV: 19612000000.0, Trodelvy: 1315000000.0, Veklury: 1799000000.0 |
| FY2025 | AmBisome: 509000000.0, Biktarvy: 14334000000.0, Descovy: 2758000000.0, Genvoya: 1498000000.0, Odefsey: 1167000000.0, Other: 290000000.0, Other HIV: 500000000.0, Other Liver Disease: 874000000.0, Royalty, contract and other revenues: 527000000.0, Sofosbuvir/Velpatasvir: 1272000000.0, Symtuza - Revenue share: 495000000.0, Tecartus: 344000000.0, Trodelvy: 1397000000.0, Veklury: 911000000.0, Vemlidy: 1070000000.0, Yescarta: 1495000000.0 |
| Period | Value |
|---|---|
| FY2010 | France: 519700000.0, Germany: 274991000.0, Italy: 345189000.0, Other European Countries: 665237000.0, Other International: 4280032000.0, Spain: 456647000.0, Switzerland: 458606000.0, United Kingdom: 450368000.0, UNITED STATES: 4224035000.0 |
| FY2011 | France: 587292000.0, Germany: 370403000.0, Italy: 392052000.0, Other European Countries: 578792000.0, Other International: 652343000.0, Spain: 498201000.0, Switzerland: 179582000.0, United Kingdom: 518377000.0, UNITED STATES: 4608343000.0 |
| FY2012 | Europe: 3332824000.0, Other International: 777705000.0, UNITED STATES: 5591988000.0 |
| FY2013 | Europe: 3613414000.0, Other International: 893096000.0, UNITED STATES: 6695178000.0 |
| FY2014 | Europe: 5442000000.0, Other International: 1266000000.0, UNITED STATES: 18182000000.0 |
| FY2015 | Europe: 7528000000.0, Other International: 3877000000.0, UNITED STATES: 21234000000.0 |
| FY2016 | Europe: 6365000000.0, JAPAN: 2527000000.0, Other International: 2144000000.0, UNITED STATES: 19354000000.0 |
| FY2017 | Europe: 5311000000.0, Other International: 2602000000.0, UNITED STATES: 18194000000.0 |
| FY2018 | Europe: 4006000000.0, Other International: 1852000000.0, UNITED STATES: 16269000000.0 |
| FY2019 | Europe: 3811000000.0, Other International: 1993000000.0, UNITED STATES: 16645000000.0 |
| FY2020 | Europe: 4135000000.0, Other International: 2337000000.0, UNITED STATES: 18217000000.0 |
| FY2021 | Europe: 4874000000.0, Other International: 3164000000.0, UNITED STATES: 19267000000.0 |
| FY2022 | Europe: 4469000000.0, Other International: 3928000000.0, UNITED STATES: 18884000000.0 |
| FY2023 | Europe: 4310000000.0, Other International: 3368000000.0, UNITED STATES: 19438000000.0 |
| FY2024 | Europe: 4634000000.0, Other International: 3529000000.0, UNITED STATES: 20591000000.0 |
| FY2025 | Europe: 5064000000.0, Other International: 3503000000.0, UNITED STATES: 20876000000.0 |
Insights · Dividends · Forecast · Financials · Learn